Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:IMDX

Oncocyte Q3 2025 Earnings Report

Oncocyte logo
$3.44 -0.03 (-0.86%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$3.52 +0.08 (+2.18%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Oncocyte EPS Results

Actual EPS
-$0.34
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oncocyte Revenue Results

Actual Revenue
$0.26 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oncocyte Announcement Details

Quarter
Q3 2025
Date
11/10/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Oncocyte Earnings Headlines

Oncocyte (NASDAQ:IMDX) Stock Rating Cut to Sell at Wall Street Zen
October 3 at 1:25 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081354
Contrasting Oncocyte (IMDX) & Its Competitors
October 1 at 6:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073780
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel
October 3 at 1:00 AM  |  Altimetry (Ad)
Head to Head Analysis: Oncocyte (IMDX) and The Competition
October 1 at 5:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073532
Comparing Precision BioSciences (NASDAQ:DTIL) & Oncocyte (NASDAQ:IMDX)
October 1 at 4:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073318
Analyzing Oncocyte (IMDX) & Its Rivals
September 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31062994
See More Oncocyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oncocyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncocyte and other key companies, straight to your email.

About Oncocyte

Oncocyte (NASDAQ:IMDX)oration is a molecular diagnostics company focused on developing and commercializing tests intended to support cancer treatment decisions. Its technologies use genomic and other molecular information to help physicians assess disease characteristics, recurrence risk, and potential response to therapy.

The company’s historical product portfolio has included DetermaRx, a genomic test designed to identify patients with early-stage lung cancer who may face a higher risk of recurrence after surgery, and DetermaIO, which was developed to help evaluate the tumor immune environment and potential response to immunotherapy. Oncocyte has also pursued tests for evaluating the likelihood that lung nodules are malignant.

Oncocyte was founded in 2009 and has focused primarily on oncology applications in the United States, working with physicians, laboratories, and health care providers. The company has undergone strategic and corporate changes over time, including transactions involving its diagnostic assets. Publicly available information about its current leadership and operations under the NASDAQ symbol IMDX is limited.

View Oncocyte Profile
Earnings Tools